ARCT - Arcturus Therapeutics Holdings Inc. -  [ ]

Ticker Details
Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Ltd is a biotechnology company developing novel RNA medicines. The company develops novel RNA medicines in therapeutic areas including infectious disease, cystic fibrosis, nonalcoholic steatohepatitis (NASH) and rare liver diseases.
IPO Date: May 22, 2013
Sector: Healthcare
Industry: Biotech
Market Cap: $199.81M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.95 | 3.81%
Avg Daily Range (30 D): $0.27 | 3.19%
Avg Daily Range (90 D): $0.21 | 2.69%
Institutional Daily Volume
Avg Daily Volume: .27M
Avg Daily Volume (30 D): .36M
Avg Daily Volume (90 D): .42M
Trade Size
Avg Trade Size (Sh.): 65
Avg Trade Size (Sh.) (30 D): 54
Avg Trade Size (Sh.) (90 D): 60
Institutional Trades
Total Institutional Trades: 2,096
Avg Institutional Trade: $2.04M
Avg Institutional Trade (30 D): $1.12M
Avg Institutional Trade (90 D): $.7M
Avg Institutional Trade Volume: .07M
Avg Institutional Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $2.28M
Avg Closing Trade (30 D): $1.12M
Avg Closing Trade (90 D): $.81M
Avg Closing Volume: 79.33K
 
News
Mar 23, 2026 @ 11:07 AM
These Are the Only 3 Stocks That Cathie Wood Bough...
Source: Rick Munarriz
Oct 23, 2025 @ 1:15 PM
Cathie Wood Goes Shopping: 3 Stocks She Just Bough...
Source: Rick Munarriz
Sep 29, 2025 @ 5:35 PM
10 Health Care Stocks With Whale Alerts In Today's...
Source: Benzinga Staff Writer
Aug 5, 2025 @ 10:00 AM
Lipid Nanoparticles Market Industry Trends, Key Gr...
Source: Researchandmarkets.Com
Jul 18, 2025 @ 8:56 AM
RNA Therapeutics and RNA Vaccines Market Industry ...
Source: Researchandmarkets.Com
Financials
  TTM Q1 2026 Q4 2025
Basic EPS $-2.83 $-.95 $-1.05
Diluted EPS $-2.83 $-.95 $-1.05
Revenue $54.71M $2.06M $7.2M
Gross Profit
Net Income / Loss $-78.67M $-26.96M $-29.08M
Operating Income / Loss $-88.37M $-28.93M $-31.31M
Cost of Revenue
Net Cash Flow $-60.43M $-19.39M $-4.45M
PE Ratio    
Splits
Nov 16, 2017 1:7